McDermott Will & Emery Represents Innate Pharma in Acquisition of Anti-C5aR
McDermott Will & Emery represented Innate Pharma, a clinical-stage biotechnology company, in its purchase of Anti-C5aR from Novo Nordisk A/S, a global healthcare company.
According the terms of the agreement, Novo Nordisk A/S grants Innate Pharma full worldwide exclusive rights to develop and commercialize a first-in-class clinical-stage anti-C5aR antibody (IPH5401) representing a novel therapeutic approach in immuno-oncology.